Empowered Patient Podcast

Christophe Bancel, Co-Founder and CEO, TISSIUM is determined to change the way body and tissue repair during surgical procedures is conducted. Rather than the old techniques such as suturing, stapling and screwing that induce trauma to the body, TISSIUM believes that tissue reconstruction should be atraumatic. Inventing a new bio material based on polymer chemistry, TISSIUM is showing dramatic results in peripheral nerve damage repair where surgeons insert the nerve into a tiny chamber made out of the polymer through 3D printing.

@TISSIUMtech #tissuereconstruction #bodyrepair

TISSIUM.com

Listen to the podcast here

Christophe Bancel, Co-Founder and CEO, TISSIUM is determined to change the way body and tissue repair during surgical procedures is conducted. Rather than the old techniques such as suturing, stapling and screwing that induce trauma to the body, TISSIUM believes that tissue reconstruction should be atraumatic. Inventing a new bio material based on polymer chemistry, TISSIUM is showing dramatic results in peripheral nerve damage repair where surgeons insert the nerve into a tiny chamber made out of the polymer through 3D printing.

@TISSIUMtech #tissuereconstruction #bodyrepair

TISSIUM.com

Download the transcript here

Joseph Hernandez, Founder and CEO, Blue Water Vaccines identifies the underlying discover about the nature of the influenza virus which is driving the development of a novel universal flu vaccine that would be administered once for lifelong immunization. The economic and health implications of this vaccine include overcoming challenges of manufacturing, storage, allocation, shipping and administering the yearly flu vaccine, all issues highlighted by the recent efforts to roll out the COVID-19 vaccine.

#BlueWaterVaccines #universalfluvaccine #influenza #flu #COVID19

BlueWaterVaccines.com

Listen to the podcast here

Joseph Hernandez, Founder and CEO, Blue Water Vaccines identifies the underlying discover about the nature of the influenza virus which is driving the development of a novel universal flu vaccine that would be administered once for lifelong immunization. The economic and health implications of this vaccine include overcoming challenges of manufacturing, storage, allocation, shipping and administering the yearly flu vaccine, all issues highlighted by the recent efforts to roll out the COVID-19 vaccine.

#BlueWaterVaccines #universalfluvaccine #influenza #flu #COVID19

BlueWaterVaccines.com

Download the transcript here

Scott Megaffin, CEO, Adastra Pharmaceuticals has taken on the challenge of developing first-in-class innovative therapeutics for the treatment of cancers with high unmet needs such as high-grade gliomas. He talks about the Phase 1b clinical trial conducted by the National Cancer Institute evaluating zotiraciclib, a potent oral cyclin-dependent kinase 9 inhibitor in combination with temozolomide in patients with recurrent brain cancer and possibly in the future to treat first-line glioma and other forms of glioma as well.

#Glioblastoma #braintumor #drugdevelopment #braincancer #NCI

AdastraRx.com

Listen to the podcast here

Scott Megaffin, CEO, Adastra Pharmaceuticals has taken on the challenge of developing first-in-class innovative therapeutics for the treatment of cancers with high unmet needs such as high-grade gliomas. He talks about the Phase 1b clinical trial conducted by the National Cancer Institute evaluating zotiraciclib, a potent oral cyclin-dependent kinase 9 inhibitor in combination with temozolomide in patients with recurrent brain cancer and possibly in the future to treat first-line glioma and other forms of glioma as well.

#Glioblastoma #braintumor #drugdevelopment #braincancer #NCI

AdastraRx.com

Download the transcript here

Eric Rosow, CEO and Co-Founder, Diameter Health shines light on the new ONC Cures Act and the significance of the Patient Access rule that mandates interoperability technology standards for payers. The primary purpose of the interoperability rules is to enable patients to have secure access to their own health data. The rules also establish the Fast Healthcare Interoperability Resource (FHIR) a standard to facilitate working with clinical data often characterized by inconsistency and presented in a variety of formats.

@diameterhealth #Optuminsight. #healthdata. #FHIR. #HL7

DIameterHealth.com

Listen to the podcast here

Eric Rosow, CEO and Co-Founder, Diameter Health shines light on the new ONC Cures Act and the significance of the Patient Access rule that mandates interoperability technology standards for payers. The primary purpose of the interoperability rules is to enable patients to have secure access to their own health data. The rules also establish the Fast Healthcare Interoperability Resource (FHIR) a standard to facilitate working with clinical data often characterized by inconsistency and presented in a variety of formats.

@diameterhealth #Optuminsight. #healthdata. #FHIR. #HL7

DIameterHealth.com

Download the transcript here

Maina Bhaman, Partner, Capital Funds, Sofinnova Partners has a long record as a successful healthcare investor in oncology, hearing, cardiovascular and cell and gene therapy. She talks about their recent investments in Myricx Pharma, a startup from Imperial College and the Francis Crick Institute in London focused on inhibiting the NMT enzyme to kill MYC-driven cancer cells and Catamaran Bio focusing on CAR-NK cells to kill solid tumors by addressing the tumor microenvironment.

#SofinnovaPartners #Biotech #Funding #CARNK #Cancer

SofinnovaPartners.com

Listen to the podcast here

Maina Bhaman, Partner, Capital Funds, Sofinnova Partners has a long record as a successful healthcare investor in oncology, hearing, cardiovascular and cell and gene therapy. She talks about their recent investments in Myricx Pharma, a startup from Imperial College and the Francis Crick Institute in London focused on inhibiting the NMT enzyme to kill MYC-driven cancer cells and Catamaran Bio focusing on CAR-NK cells to kill solid tumors by addressing the tumor microenvironment.

#SofinnovaPartners #Biotech #Funding #CARNK #Cancer

SofinnovaPartners.com

Download the transcript here